Summary
(−)-Deprenyl (0.25 or 2mg/kg) or saline was injected daily into male Wistar rats for 3 weeks. The striata were dissected out and soluble and particulate Superoxide dismutase activity measured. (−)-Deprenyl at 2mg/kg induced a significant increase in the soluble but not the particulate form of the enzyme. The possibility that this action contributes to the ability of (−)-deprenyl to retard nigral degeneration in man and prolong life in rats is discussed.
Similar content being viewed by others
References
Birkmayer W, Knoll J, Riederer P, Youdim MBH (1983) (−)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Mod Probl Pharmacopsychiatry 19: 170–176
Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in Parkinson's disease: a long term study. J Neural Transm 64: 113–127
Braestrup C, Andersen H, Randrup A (1975) The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Eur J Pharmacol 34: 181–187
Carrillo M-C, Kanai S, Nokubo M, Kitani K (1991) (−)-Deprenyl induces activities of both Superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 48: 517–521
Ceballos I, Lafon M, Javoy Agid F, Hirsch E, Nicole A, Sinet PM, Agid Y (1990) Superoxide dismutase and Parkinson's disease. Lancet i: 1035–1036
Glover V, Sandier M, Owen F, Riley GJ (1977) Dopamine is a monoamine oxidase B substrate in man. Nature 265: 80–81
Knoll J (1988) The striatal dopamine dependency of lifespan in male rats. Longevity study with (−)-deprenyl. Mech Ageing Dev 46: 237–262
Knoll J, Dallo J, Yen TT (1989) Striatal dopamine, sexual activity and lifespan longevity of rats treated with (−)-deprenyl. Life Sci 45: 525–531
Marttila RJ, Lorenz H, Rinne UK (1988) Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of Superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 86: 321–331
Marttila RJ, Viljanen M, Toivonen E, Lorentz H, Rinne UK (1990) Superoxide dismutaselike activity in the Parkinson's disease brain. Adv Neurol 53: 141–144
Milgram NW, Racine RJ, Nellis P, Mendonca A, Ivy GO (1990) Maintenance on L-deprenyl prolongs life in aged male rats. Life Sci 47: 415–420
Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P, Marsden CD (1989) A selective increase in particulate Superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 53: 692–697
Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245: 519–522
The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321: 1364–1371
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Clow, A., Hussain, T., Glover, V. et al. (−)-Deprenyl can induce soluble superoxide dismutase in rat striata. J. Neural Transmission 86, 77–80 (1991). https://doi.org/10.1007/BF01250378
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01250378